Journal of Traditional Chinese Medicine ›› 2020, Vol. 40 ›› Issue (1): 103-111.DOI: 10.19852/j.cnki.jtcm.2020.01.011

Previous Articles     Next Articles

Efficacy and safety of Yiqi Huoxue Jiedu decoction for the treatment of advanced epithelial ovarian cancer patients: a double-blind randomized controlled clinical trial

Li Yifan, Li Juan, Fan Bifa, Wang Yitong, Jiang Juling, Zhang Zhenhua, Wang Xinxing, Lu Wenping   

  1. Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences;Department of Graduate School, Beijing University of Chinese Medicine;Department of Graduate School, China Academy of Chinese Medical Sciences;Department of Pain, China-Japan Friendship Hospital;
  • Online:2020-02-15 Published:2020-02-15
  • Supported by:
    Supported by National Natural Science Foundation of China(NSFC)-funded Project:the Mechanisms of Tailored Immunotherapy of Yiqi Huoxue Jiedu Decoction Modulating T Regulatory Cells at the Level of the Tumor Microenvironment and Inherited Single Nucleotide Polymorphisms in Advanced Ovarian Cancer(No.81473566)

Abstract: OBJECTIVE: To further evaluate the complementary effect of Yiqi Huoxue Jiedu decoction(YHJD) on patients with advanced epithelial ovarian cancer(EOC).METHODS: All 330 enrolled participants diagnosed with stage Ⅲc EOC were randomly divided into two groups that received YHJD or a placebo. The primary end point was health-related quality of life(HRQL) measured by the functional assessment of cancer therapy-ovary cancer(FACT-O) questionnaire. The secondary end point was progression-free survival(PFS).RESULTS: A total of 299 participants completed the trial with 153 and 146 in YHJD and control groups,respectively. After 6 months of treatment, YHJD increased physical wellbeing(PWB), functional wellbeing(FWB), additional concerns(AC), and the trial outcome index(TOI)(P < 0.05) by various degrees compared with the baseline. YHJD also had notable advantages over the placebo at 3 and 6 months in terms of PWB, FWB, AC(P < 0.05), and TOI(P < 0.01).In addition, YHJD had a significant advantage in terms of PFS compared with the placebo(21 vs18 months, P < 0.05). No adverse events were reported.CONCLUSION: YHJD is an effective and safe choice as a complementary therapy to improve HRQL and prolong PFS of stage Ⅲc EOC patients.

Key words: Ovarian neoplasms, Quality of life, Disease-free survival, Yiqi Huoxue Jiedu decoction, Randomized controlled trial

Cite this article

Li Yifan, Li Juan, Fan Bifa, Wang Yitong, Jiang Juling, Zhang Zhenhua, Wang Xinxing, Lu Wenping. Efficacy and safety of Yiqi Huoxue Jiedu decoction for the treatment of advanced epithelial ovarian cancer patients: a double-blind randomized controlled clinical trial[J]. Journal of Traditional Chinese Medicine, 2020, 40(1): 103-111.